

## Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Donna E. Reece, MD
Name of drug and indication under review:	Daratumumab -VMP

## **Conflict of Interest Declaration**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

#### **Section A: Payment Received**

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
  - 🛛 Yes
  - 🗆 No

If no, please go to Section B.

2. What form of payment did you receive? (Check all that apply.)

Advisory role (e.g., advisory boards, health technology assessment submission advice)	<ul> <li>Program or Operating Funding (e.g., website)</li> </ul>		
Conference attendance	Research/educational grants		
□ Royalties	□ Travel grants		
□ Gifts	Sponsorship of events		
🗆 Honoraria	Other, please specify:		

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Janssen honoraria for Health Canada presentations, unrestricted educational talks and local / national advisory boards:

Research funding: per patient payment for MCRN 004 study: \$ and patient payment for MCRN 009 \$



Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

NO

## Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

NO

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

14 January 2019 Date Donna E Reece, MD Name

Signature

# Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Julie Stakiw

Name of drug and indication under review: Dara-VMP

## **Conflict of Interest Declaration**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

## **Section A: Payment Received**

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
  - $\boxtimes$  Yes
  - 🗆 No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, health technology assessment submission advice)
     Conference attendance
     Royalties
     Gifts
     Sponsorship of events
     Honoraria
     Other, please specify:
- 3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

I have received honoraria for attending advisory board from Celgene, Janssen, and Takeda totalling approximately



Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

NA

## Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

NA

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

14/01/2019

Dr Julie Stakiw

Date

Name

Signature

# Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr. Rodger Tiedemann

Name of drug and indication under review: Daratumumab VMP

## **Conflict of Interest Declaration**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

### **Section A: Payment Received**

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
  - $\boxtimes$  Yes
  - 🗆 No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, health technology assessment submission advice)
     Conference attendance
     Royalties
     Gifts
     Gifts
     Sponsorship of events
     Honoraria
     Other, please specify:
- 3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Janssen: Oct 2017 - \$ (honorarium) + (expenses to attend a myeloma investigators meeting in Alberta. I estimate receiving another Janssen adboard payment reimbursement of (for a less within the past two years, but could not readily find the record.



Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

No

## Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

R. Tiedemann 15 Jan 2019 Date Name

his.

Signature

# Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Dr. Kevin Song		
Name of drug and indication under review:	Dara-VMP		

## **Conflict of Interest Declaration**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

## **Section A: Payment Received**

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
  - $\Box$  Yes
  - 🖂 No

If no, please go to Section B.

2. What form of payment did you receive? (Check all that apply.)

Advisory role (e.g., advisory boards, health technology assessment submission advice)	<ul> <li>Program or Operating Funding (e.g., website)</li> </ul>
Conference attendance	☑ Research/educational grants
□ Royalties	⊠ Travel grants
□ Gifts	□ Sponsorship of events
🗆 Honoraria	Other, please specify:
	-

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Takeda \$ Janssen \$ Celgene \$ and Amgen \$



Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

No

## Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

Date Date Name Kevih Jong

Signature

# Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Dr. Michel Pavic
Name of drug and indication under review:	Dara-VMP

## **Conflict of Interest Declaration**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

## **Section A: Payment Received**

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
  - $\boxtimes$  Yes
  - 🗆 No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, health technology assessment submission advice)
     Conference attendance
     Royalties
     Gifts
     Gifts
     Sponsorship of events
     Other, please specify:
- 3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

\$		



Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

No

## Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

2019/01/13

Pavic Michel

Date

Name

Signature

# Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Dr. Sathish Gopalakrishnan Name of registered clinician:

Name of drug and indication under review: Dara-VMP

## **Conflict of Interest Declaration**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

## Section A: Payment Received

- Have you received any payments over the previous two years from any company or organization that may have a direct or 1. indirect interest in the drug under review?
  - ⊠ Yes
  - 🗆 No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, health □ Program or Operating Funding technology assessment submission advice) (e.g., website) □ Conference attendance Research/educational grants Royalties □ Travel grants □ Gifts □ Sponsorship of events □ Other, please specify: Honoraria
- 3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Janssen \$			
Celgene \$			



Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

NA

## Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

NA

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

15/51/2019 Gopalalaulman-

Signature

# Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: D

Dr. Roman Foley

Name of drug and indication under review: Daratumumab -VMP

## **Conflict of Interest Declaration**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

## **Section A: Payment Received**

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
  - ⊠ Yes
  - 🗆 No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, health technology assessment submission advice)
     Conference attendance
     Royalties
     Travel grants
  - □ Gifts □ Sponsorship of events
  - 🗆 Honoraria

- □ Other, please specify:
- 3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Celgene \$			
Janssen \$			
Takeda \$			



Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

NO

## Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

NO

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

Signature

16/1/2019 RONAN Foly Date // 2019 Name

Clinician Input Template for CADTH pan-Canadian Oncology Drug Review Program



Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

# pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr. Tom Kouroukis

Name of drug and indication under review: DVMP/MM

### **Conflict of Interest Declarations**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

#### Section A: Payment Received

Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
 Yes
 No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, HTA submission advice)
  - Conference attendance
  - Royalties
  - □ Gifts
  - Honoraria
  - Other, please specify: Click here to enter text.
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

×

Roche - Funding to the hospital for dinical trial

Program or Operating Funding

Research/educational grants

Sponsorship of Events

(e.g., website)

Travel grants

1



Before completing this template, be sure to register with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

#### Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

### Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: March 29th, 2018

Name:

Signature:

Click here to enter text.

pCODR Clinician Input on a Drug Review

© February 2016 CADTH-pCODR | PAN CANADIAN ONCOLOGY DRUG REVIEW

2